Trial Profile
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 18 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Dec 2013 Final results presented at the 36th Annual San Antonio Breast Cancer Symposium.
- 12 Nov 2013 Planned End Date changed from 1 Sep 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.